Sophie Vandebroek, Michael Klobuchar Join Revvity’s Board

Revvity Inc.’s has anmed Sophie Vandebroek, Ph.D., and Michael Klobuchar to its Board of Directors.
 
“I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” Revvity Board Chairman Alexis Michas said. “Sophie brings deep acumen in AI, business processes, sustainability, and cybersecurity, along with academic advisory experience and leadership in global organizations. The board will benefit from her long track record of innovation and managing balanced research and development portfolios at large, diverse and inclusive organizations. Mike joins our board with a wealth of experience in developing and implementing strategic and operational initiatives for complex global enterprises. His depth and breadth of expertise across technical, operational, financial roles—and his deep commitment to scientific innovation—will provide the board with valuable insights to help propel Revvity forward. I would also like to thank Dr. Sylvie Gregoire for her guidance serving on Revvity’s board since 2015, as she has decided not to stand for re-election after she finishes her current term at our annual shareholder meeting in April.” 
 
Dr. Vandebroek founded and owns Strategic Vision Ventures, an innovation consulting firm. Previously, she was Massachusetts Institute of Technology’s Inaugural School of Engineering Visiting Scholar. Until 2019 she was vice president of Emerging Technology Partnerships at IBM. Dr. Vandebroek also was chief operating officer of IBM Research. Prior to joining IBM, she was chief technology officer and president of the Xerox Innovation Group. Dr. Vandebroek led Xerox’s global laboratories, including PARC Inc., where she chaired the board for eight years. Earlier in her career, Dr. Vandebroek was Xerox’s chief engineer and prior to that, vice president of Xerox’s Canadian Research Center.
 
Dr. Vandebroek is also a member of the Board of Directors of IDEXX Laboratories (IDXX), Inari Agriculture, and Wolters Kluwer N.V. Previously she served on the Board of Directors of Analogic and Nypro Corporation. She holds 14 U.S. patents and is a Fellow of the Institute of Electrical & Electronics Engineers (IEEE) and a Fellow of the Belgian-American Educational Foundation. Dr. Vandebroek earned a bachelor’s and master’s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a Ph.D in electrical engineering from Cornell University.
 
Klobuchar is executive vice president and chief strategy officer at Merck & Co. Inc. He is a member of Merck’s Executive Committee, and has served in his current role since 2021, overseeing the leadership, conception, planning and execution of strategies to achieve Merck’s vision, mission and business objectives. He is also responsible for setting and executing the company’s global business development and M&A strategies as well as leading the digital, data and IT infrastructure and cybersecurity strategies. Klobuchar prioritizes and pursues enterprise investment opportunities that modernize and expand the company’s innovation pipeline and technology portfolio across discovery, development, manufacturing and commercial. He has guided the company through more than $25 billion in M&A activity over the last three years.
 
Since joining Merck in 1998, Klobuchar has held positions of increasing responsibility in research, manufacturing, commercial planning, finance and strategy. Following the merger of Merck and Shering-Plough, he led key elements in the integration of the companies’ research operations. From 2019 to 2021, Klobuchar was senior vice president, chief financial officer, and head of Portfolio and Alliance Management for Merck Research Laboratories, the company’s $13 billion research and development organization. Klobuchar earned an MBA from Villanova University, a master’s degree in chemical engineering from Rutgers University, and a bachelor’s degree from Purdue University.
 
Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity’s specialized focus areas include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics, among others. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.